Literature DB >> 24362588

Soluble N-terminal fragment of mutant Huntingtin protein impairs mitochondrial axonal transport in cultured hippocampal neurons.

Jun Tian1, Ya-Ping Yan, Rui Zhou, Hui-Fang Lou, Ye Rong, Bao-Rong Zhang.   

Abstract

Huntington's disease (HD) is an autosomal dominant, progressive, neurodegenerative disorder caused by an unstable expansion of CAG repeats (>35 repeats) within exon 1 of the interesting transcript 15 (IT15) gene. This gene encodes a protein called Huntingtin (Htt), and mutation of the gene results in a polyglutamine (polyQ) near the N-terminus of Htt. The N-terminal fragments of mutant Htt (mHtt), which tend to aggregate, are sufficient to cause HD. Whether these aggregates are causal or protective for HD remains hotly debated. Dysfunctional mitochondrial axonal transport is associated with HD. It remains unknown whether the soluble or aggregated form of mHtt is the primary cause of the impaired mitochondrial axonal transport in HD pathology. Here, we investigated the impact of soluble and aggregated N-terminal fragments of mHtt on mitochondrial axonal transport in cultured hippocampal neurons. We found that the N-terminal fragment of mHtt formed aggregates in almost half of the transfected neurons. Overexpression of the N-terminal fragment of mHtt decreased the velocity of mitochondrial axonal transport and mitochondrial mobility in neurons regardless of whether aggregates were formed. However, the impairment of mitochondrial axonal transport in neurons expressing the soluble and aggregated N-terminal fragments of mHtt did not differ. Our findings indicate that both the soluble and aggregated N-terminal fragments of mHtt impair mitochondrial axonal transport in cultured hippocampal neurons. We predict that dysfunction of mitochondrial axonal transport is an early-stage event in the progression of HD, even before mHtt aggregates are formed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24362588      PMCID: PMC5562578          DOI: 10.1007/s12264-013-1393-0

Source DB:  PubMed          Journal:  Neurosci Bull        ISSN: 1995-8218            Impact factor:   5.203


  26 in total

Review 1.  Huntington's disease.

Authors:  Ainhi D Ha; Victor S C Fung
Journal:  Curr Opin Neurol       Date:  2012-08       Impact factor: 5.710

Review 2.  Protein aggregates in Huntington's disease.

Authors:  Montserrat Arrasate; Steven Finkbeiner
Journal:  Exp Neurol       Date:  2011-12-19       Impact factor: 5.330

3.  Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice.

Authors:  L Mangiarini; K Sathasivam; M Seller; B Cozens; A Harper; C Hetherington; M Lawton; Y Trottier; H Lehrach; S W Davies; G P Bates
Journal:  Cell       Date:  1996-11-01       Impact factor: 41.582

4.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

Authors: 
Journal:  Cell       Date:  1993-03-26       Impact factor: 41.582

Review 5.  Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease.

Authors:  P Hemachandra Reddy; Ulziibat P Shirendeb
Journal:  Biochim Biophys Acta       Date:  2011-11-04

Review 6.  Comprehensive treatment of Huntington disease and other choreic disorders.

Authors:  Carlos Singer
Journal:  Cleve Clin J Med       Date:  2012-07       Impact factor: 2.321

Review 7.  Axonal transport and neurodegenerative disease: can we see the elephant?

Authors:  Lawrence S B Goldstein
Journal:  Prog Neurobiol       Date:  2012-04-01       Impact factor: 11.685

Review 8.  Molecular mechanisms and potential therapeutical targets in Huntington's disease.

Authors:  Chiara Zuccato; Marta Valenza; Elena Cattaneo
Journal:  Physiol Rev       Date:  2010-07       Impact factor: 37.312

9.  Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons.

Authors:  Diane T W Chang; Gordon L Rintoul; Sruthi Pandipati; Ian J Reynolds
Journal:  Neurobiol Dis       Date:  2006-02-09       Impact factor: 5.996

10.  HDAC6 inhibitor blocks amyloid beta-induced impairment of mitochondrial transport in hippocampal neurons.

Authors:  Chaeyoung Kim; Heesun Choi; Eun Sun Jung; Wonik Lee; Soojung Oh; Noo Li Jeon; Inhee Mook-Jung
Journal:  PLoS One       Date:  2012-08-22       Impact factor: 3.240

View more
  4 in total

Review 1.  Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders.

Authors:  Dharmendra Kumar Khatri; Amey Kadbhane; Monica Patel; Shweta Nene; Srividya Atmakuri; Saurabh Srivastava; Shashi Bala Singh
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-04-08

2.  Oxidative metabolism and Ca2+ handling in isolated brain mitochondria and striatal neurons from R6/2 mice, a model of Huntington's disease.

Authors:  James Hamilton; Jessica J Pellman; Tatiana Brustovetsky; Robert A Harris; Nickolay Brustovetsky
Journal:  Hum Mol Genet       Date:  2016-04-30       Impact factor: 6.150

Review 3.  Transcription, epigenetics and ameliorative strategies in Huntington's Disease: a genome-wide perspective.

Authors:  Luis M Valor
Journal:  Mol Neurobiol       Date:  2014-05-01       Impact factor: 5.590

Review 4.  Selective Neuron Vulnerability in Common and Rare Diseases-Mitochondria in the Focus.

Authors:  Thomas Paß; Rudolf J Wiesner; David Pla-Martín
Journal:  Front Mol Biosci       Date:  2021-06-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.